The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes

Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 diabetes and atherosclerosis in animal models of diabetes. However, it still remains unclear if the anti‐atherosclerotic effect of SGLT2 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Masahiko, Kubota, Tetsuya, Sakurai, Yoshitaka, Wada, Nobuhiro, Shioda, Seiji, Yamauchi, Toshimasa, Kadowaki, Takashi, Kubota, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201373/
https://www.ncbi.nlm.nih.gov/pubmed/35707828
http://dx.doi.org/10.1002/prp2.971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201373/
https://www.ncbi.nlm.nih.gov/pubmed/35707828
http://dx.doi.org/10.1002/prp2.971

Ejemplares similares